Obesity Drug Labeling Updated with New Interaction, Side Effect

Quick Hits: Transvaginal Mesh Pulled, New Weight Loss Drug & More

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application for Xenical (obesity management drug) regarding new drug interactions and adverse reaction updates to its labeling. Xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. The product labeling has been updated to include a possible drug interaction with amiodarone (treats life-threatening heart rhythm problems). Via MPR. Posted August 17, 2015.

–Alanna McCatty


Alanna McCatty

Alanna McCatty

Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.


Did you find this article helpful?


Latest News

Prenatal Opioid Exposure Can Harm Children and Teens

Prenatal Opioid Exposure Can Harm Children and Teens

Most infants born with Prenatal Opioid Exposure (POE) look and seem completely unaffected – even those that go through withdrawal. A new meta-analysis shows that brain development and motor skills in children exposed to opioids in pregnancy lag behind other children significantly.

  • Advertisement